Piper Sandler initiated coverage of Apellis with a Neutral rating and $46 price target. The firm cites “dampened enthusiasm” for Syfovre because of vasculitis events for the Neutral rating. Piper’s survey suggests the majority of ophthalmologists expect to decrease use of Syfovre, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis shares ‘undervalued’ at current levels, says UBS
- Apellis trial results reaffirm confidence ahead of VALIANT readout, says Stifel
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- Apellis, Sobi present one-year data from Phase 2 study of pegcetacoplan
- Apellis price target lowered to $48 from $57 at Wells Fargo